Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna

A Lallas^{1

2}, E Moscarella³, H Kittler⁴, C Longo^{5

6}, L Thomas^{7

8

9}, I Zalaudek¹⁰, A Kyrgidis¹¹, S M Manoli^{1

2}, N di Meo¹⁰, C Papageorgiou^{2

12}, Z Apalla^{2

12}, G Argenziano³

Affiliations

¹ First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² DERMOMEDICA Dermatology Unit, Thessaloniki, Greece.
³ Dermatology Unit, University of Campania, Naples, Italy.
⁴ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
⁵ Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
⁶ Azienda Unita Sanitaria Locale - IRCCS di Reggio Emilia, Centro Oncologico ad Alta Tecnologia Diagnostica-Dermatologia, Reggio Emilia, Italy.
⁷ Department of Dermatology, Hospital Lyon Sud, France.
⁸ Lyon 1 University, Lyon, France.
⁹ Lyons cancer research center INSERM U1052-CNRS UMR5286, France.
¹⁰ Department of Dermatology, University of Trieste, Italy.
¹¹ Department of Oral & Maxillofacial Surgery, Aristotle University of Thessaloniki, Greece.
¹² Second Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

Free article

A Lallas et al. Br J Dermatol. 2021 Sep.

Free article

. 2021 Sep;185(3):675-677.

doi: 10.1111/bjd.20407. Epub 2021 Jul 5.

¹ First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² DERMOMEDICA Dermatology Unit, Thessaloniki, Greece.
³ Dermatology Unit, University of Campania, Naples, Italy.
⁴ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
⁵ Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
⁶ Azienda Unita Sanitaria Locale - IRCCS di Reggio Emilia, Centro Oncologico ad Alta Tecnologia Diagnostica-Dermatologia, Reggio Emilia, Italy.
⁷ Department of Dermatology, Hospital Lyon Sud, France.
⁸ Lyon 1 University, Lyon, France.
⁹ Lyons cancer research center INSERM U1052-CNRS UMR5286, France.
¹⁰ Department of Dermatology, University of Trieste, Italy.
¹¹ Department of Oral & Maxillofacial Surgery, Aristotle University of Thessaloniki, Greece.
¹² Second Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

No abstract available

References

1. Moyer JS, Rudy S, Boonstra PS et al. Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol 2017; 153:282-8.
1. Nosrati A, Berliner JG, Goel S et al. Outcomes of melanoma in situ treated with Mohs micrographic surgery compared with wide local excision. JAMA Dermatol 2017; 153:436-41.
1. Kirtschig G, van Meurs T, van Doorn R. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate. Acta Derm Venereol 2015; 95:83-5.
1. Tio D, van der Woude J, Prinsen CAC et al. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol 2017; 31:616-24.
1. Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol 2015; 73:205-12.